Viracta Therapeutics Q2 2024 GAAP EPS $(0.25) Beats $(0.37) Estimate; Cash, Cash Equivalents, And Short-term Investments Of Approximately $30M Are Expected To Be Sufficient To Fund Operations Late Into The First Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics reported a Q2 2024 GAAP EPS of $(0.25), beating the estimate of $(0.37). The company has approximately $30M in cash, cash equivalents, and short-term investments, which are expected to fund operations into the first quarter of 2025.
August 14, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viracta Therapeutics reported better-than-expected Q2 2024 GAAP EPS of $(0.25) compared to the estimated $(0.37). The company has $30M in cash and investments, sufficient to fund operations into Q1 2025.
The better-than-expected earnings report and sufficient funding into Q1 2025 are positive indicators for Viracta Therapeutics. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100